We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · May 20, 2023

Safety and Efficacy of Stereotactic Ablative Radiotherapy Plus Durvalumab for Early-Stage Medically Inoperable NSCLC

International Journal of Radiation Oncology, Biology, Physics


Additional Info

Disclosure statements are available on the authors' profiles:

International Journal of Radiation Oncology, Biology, Physics
Safety and Efficacy Results From iSABR, a Phase 1 Study of Stereotactic ABlative Radiotherapy in Combination With Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer
Int. J. Radiat. Oncol. Biol. Phys 2023 Apr 05;[EPub Ahead of Print], TC Wu, A Stube, C Felix, D Oseguera, T Romero, J Goldman, EB Garon, JM Lee, J Glaspy, AE Lisberg, CG Rusthoven, DR Camidge, S Siva, B Solomon, A Lee, SE Tenn, N Shaverdian, ML Steinberg, AC Raldow, P Lee

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading